scholarly journals Current status of antifibrinolytic therapy for treatment of patients with aneurysmal subarachnoid hemorrhage.

Stroke ◽  
1982 ◽  
Vol 13 (2) ◽  
pp. 256-259 ◽  
Author(s):  
H P Adams
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Current Status ◽  
Antifibrinolytic Therapy

scholarly journals Current Status of Problems with Initial Treatment for Aneurysmal Subarachnoid Hemorrhage

2019 ◽  
Vol 28 (9) ◽  
pp. 542-551
Author(s):  
Hiroharu Kataoka ◽  
Shunsuke Nakagawa ◽  
Jun C Takahashi ◽  
Yasushi Takagi ◽  
Susumu Miyamoto
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Initial Treatment ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Current Status

Early management of aneurysmal subarachnoid hemorrhage

1981 ◽  
Vol 54 (2) ◽  
pp. 141-145 ◽  
Author(s):  
Harold P. Adams ◽  
Neal F. Kassell ◽  
James C. Torner ◽  
Donald W. Nibbelink ◽  
Adolph L. Sahs
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Medical Management ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Aneurysm Rupture ◽  
Early Management ◽  
Neurological Sequelae ◽  
Content Type ◽  
Antifibrinolytic Therapy ◽  
Effective Reduction ◽  
Fine Print

✓ The overall results are presented of early medical management and delayed operation among 249 patients studied during the period 1974 to 1977, treated within 3 days of subarachnoid hemorrhage (SAH) and evaluated 90 days after aneurysm rupture. The results included 36.2% mortality, 17.9% survival with serious neurological sequelae, and 46% with a favorable outcome. Of the patients admitted in good neurological condition, 28.7% had died and only 55.7% had a favorable recovery at 90 days after SAH. These figures represent the results despite effective reduction in early rebleeding by antifibrinolytic therapy and successful surgery in those patients reaching operation. Further therapeutic advances are needed for patients hospitalized within a few days after SAH.

Calcium Antagonists in the Management of Patients with Aneurysmal Subarachnoid Hemorrhage: A Review

Angiology ◽  
1990 ◽  
Vol 41 (11) ◽  
pp. 1010-1016 ◽  
Author(s):  
Harold P. Adams
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Cause Of Death ◽  
Calcium Antagonists ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Medical Center ◽  
Current Status ◽  
Important Complication ◽  
Arterial Vasospasm ◽  
Major Medical Center

Cerebral arterial vasospasm and infarction is the leading cause of death and disability among patients who reach a major medical center after aneurysmal subarachnoid hemorrhage (SAH). Recent evidence suggests that two calcium antagonists, nimodipine or nicardipine, may be useful in preventing this important complication of SAH. This paper reviews the current status of these two calcium antagonists in the management of SAH.

Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage

1984 ◽  
Vol 61 (2) ◽  
pp. 225-230 ◽  
Author(s):  
Neal F. Kassell ◽  
James C. Torner ◽  
Harold P. Adams
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Aneurysm Surgery ◽  
Cooperative Study ◽  
Content Type ◽  
Antifibrinolytic Therapy ◽  
Rebleeding Rate ◽  
Relationship Of ◽  
The Relationship ◽  
Fine Print

✓ Antifibrinolytic therapy remains a controversial issue in the management of subarachnoid hemorrhage (SAH). The relationship of antifibrinolytic therapy with mortality, rebleeding, ischemia, hydrocephalus, and clotting abnormalities was studied in 672 patients in the International Cooperative Study on the Timing of Aneurysm Surgery. The patients with antifibrinolytic therapy had a significantly lower rebleeding rate, but higher rates of ischemic deficits and hydrocephalus. The net result was no difference in mortality in the 1st month following the initial SAH. Further clinical trials are needed to determine the overall effects of antifibrinolytic therapy.

scholarly journals Clinical Treatment and Prognostic Analysis of Patients with Aneurysmal Subarachnoid Hemorrhage

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Xue Yang ◽  
Qiong Cheng ◽  
Yunfei Li ◽  
Zheng Zheng ◽  
Junpeng Liu ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Blood Vessels ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Physiological Mechanism ◽  
Clinical Treatment ◽  
Current Status ◽  
Prognostic Analysis ◽  
Depth Study ◽  
Serious Disease ◽  
All Diseases

Subarachnoid hemorrhage (SAH) is a serious disease caused by blood flow into the subarachnoid space due to rupture of blood vessels. All diseases that cause intracranial hemorrhage are the cause of subarachnoid hemorrhage. Among them, due to the particularity of intracranial blood vessels, intracranial blood vessels are more prone to aneurysms than other parts. Therefore, the incidence of aneurysmal subarachnoid hemorrhage (aSAH) is extremely high. The purpose of this article is to study the clinical treatment and prognosis analysis of aSAH patients. This article first summarizes the current status of SAH research at home and abroad and summarizes its potential value and significance. On this basis, an in-depth study of the clinical treatment of aSAH patients has been carried out. The physiological mechanism and clinical general differences of aSAH were studied and analyzed. This article systematically describes the application of CTP in the treatment and prognosis analysis of aSAH patients. Then, it will use a comparative analysis method, interdisciplinary method, and other research forms to carry out experimental research on the theme of this article. Research shows that rebleeding and blood sodium are the main factors for cerebral ischemia caused by aSAH.

Sign in / Sign up

Export Citation Format

Share Document